336 related articles for article (PubMed ID: 37236756)
41. Changes in Renal Function and Oxidative Status Associated with the Hypotensive Effects of Oleanolic Acid and Related Synthetic Derivatives in Experimental Animals.
Madlala HP; Van Heerden FR; Mubagwa K; Musabayane CT
PLoS One; 2015; 10(6):e0128192. PubMed ID: 26046776
[TBL] [Abstract][Full Text] [Related]
42. Omega-3 fatty acids and hypertension in humans.
Mori TA
Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):842-6. PubMed ID: 16922818
[TBL] [Abstract][Full Text] [Related]
43. Omega-3 polyunsaturated fatty acids and hypertension: a review of vasodilatory mechanisms of docosahexaenoic acid and eicosapentaenoic acid.
Bercea CI; Cottrell GS; Tamagnini F; McNeish AJ
Br J Pharmacol; 2021 Feb; 178(4):860-877. PubMed ID: 33283269
[TBL] [Abstract][Full Text] [Related]
44. Omega-3 fatty acids and cardiovascular disease: epidemiology and effects on cardiometabolic risk factors.
Mori TA
Food Funct; 2014 Sep; 5(9):2004-19. PubMed ID: 25062404
[TBL] [Abstract][Full Text] [Related]
45. Repeated fasting and refeeding with 20:5, n-3 eicosapentaenoic acid (EPA): a novel approach for rapid fatty acid exchange and its effect on blood pressure, plasma lipids and hemostasis.
Yosefy C; Viskoper JR; Varon D; Ilan Z; Pilpel D; Lugassy G; Schneider R; Savyon N; Adan Y; Raz A
J Hum Hypertens; 1996 Sep; 10 Suppl 3():S135-9. PubMed ID: 8872845
[TBL] [Abstract][Full Text] [Related]
46. Omega-3 fatty acids and cardiovascular disease: The epidemiological evidence.
Simopoulos AP
Environ Health Prev Med; 2002 Jan; 6(4):203-9. PubMed ID: 21432336
[TBL] [Abstract][Full Text] [Related]
47. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
Thomopoulos C; Parati G; Zanchetti A
J Hypertens; 2017 May; 35(5):922-944. PubMed ID: 28141660
[TBL] [Abstract][Full Text] [Related]
48. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
49. Lipidomic profiling of bioactive lipids by mass spectrometry during microbial infections.
Tam VC
Semin Immunol; 2013 Oct; 25(3):240-8. PubMed ID: 24084369
[TBL] [Abstract][Full Text] [Related]
50. Antihypertensive effects of peroxisome proliferator-activated receptor-β/δ activation.
Toral M; Romero M; Pérez-Vizcaíno F; Duarte J; Jiménez R
Am J Physiol Heart Circ Physiol; 2017 Feb; 312(2):H189-H200. PubMed ID: 27881385
[TBL] [Abstract][Full Text] [Related]
51. Marine OMEGA-3 fatty acids in the prevention of cardiovascular disease.
Mori TA
Fitoterapia; 2017 Nov; 123():51-58. PubMed ID: 28964873
[TBL] [Abstract][Full Text] [Related]
52. Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.
Imig JD; Jankiewicz WK; Khan AH
Hypertension; 2020 Jul; 76(1):3-15. PubMed ID: 32475311
[TBL] [Abstract][Full Text] [Related]
53. Generation of Bioactive Oxylipins from Exogenously Added Arachidonic, Eicosapentaenoic and Docosahexaenoic Acid in Primary Human Brain Microvessel Endothelial Cells.
Aukema HM; Winter T; Ravandi A; Dalvi S; Miller DW; Hatch GM
Lipids; 2016 May; 51(5):591-9. PubMed ID: 26439837
[TBL] [Abstract][Full Text] [Related]
54. Impact of Salt Intake on the Pathogenesis and Treatment of Hypertension.
Rust P; Ekmekcioglu C
Adv Exp Med Biol; 2017; 956():61-84. PubMed ID: 27757935
[TBL] [Abstract][Full Text] [Related]
55. [Influence of antihypertensive and metabolic drugs on fatty acids content of lipids in cardiomyocytes of rats with spontaneous hypertension].
Puzyrenko AM; Chekman IS; Briuzhina TS; Horchakova NO
Ukr Biokhim Zh (1999); 2013; 85(4):67-74. PubMed ID: 24319974
[TBL] [Abstract][Full Text] [Related]
56. [Essential fatty acids and lipid mediators. Endocannabinoids].
Caramia G
Pediatr Med Chir; 2012; 34(2):65-72. PubMed ID: 22730630
[TBL] [Abstract][Full Text] [Related]
57. Bioactive Lipids in Age-Related Disorders.
Das UN
Adv Exp Med Biol; 2020; 1260():33-83. PubMed ID: 32304030
[TBL] [Abstract][Full Text] [Related]
58. Docosahexaenoic acid is an antihypertensive nutrient that affects aldosterone production in SHR.
Engler MM; Engler MB; Goodfriend TL; Ball DL; Yu Z; Su P; Kroetz DL
Proc Soc Exp Biol Med; 1999 May; 221(1):32-8. PubMed ID: 10320629
[TBL] [Abstract][Full Text] [Related]
59. 2,3',4,5'-Tetramethoxystilbene prevents deoxycorticosterone-salt-induced hypertension: contribution of cytochrome P-450 1B1.
Sahan-Firat S; Jennings BL; Yaghini FA; Song CY; Estes AM; Fang XR; Farjana N; Khan AI; Malik KU
Am J Physiol Heart Circ Physiol; 2010 Dec; 299(6):H1891-901. PubMed ID: 20852048
[TBL] [Abstract][Full Text] [Related]
60. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men.
Mori TA; Watts GF; Burke V; Hilme E; Puddey IB; Beilin LJ
Circulation; 2000 Sep; 102(11):1264-9. PubMed ID: 10982541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
